ADIS LTD

What ADIS LTD does

Adis Ltd is a medical and pharmaceutical publishing company specializing in drug-focused peer-reviewed journals, drug safety intelligence, and supporting publishing services. Founded in 1960 (per firmographic record; company history references 1970) and headquartered in Auckland, New Zealand with UK offices in London and Chester, Adis operates as a subsidiary of Springer Nature following its 2015 acquisition. The company's core product is a portfolio of over 30 peer-reviewed medical journals spanning all therapeutic areas, organized into three tiers: Adis Premier Journals (established titles with high Impact Factors and traditional subscription access), Adis Rapid+ Journals (open access titles with 2-week peer review and personalized concierge service), and Adis Open Access Journals (fully open access under CC BY-NC licensing). Specialized sub-brands include Adis Drug Reviews (definitive drug evaluations and Q&As), the Reactions Weekly drug safety newsletter (monitoring 8,000+ indexed titles), and Digital Features & Plain Language Summaries. The underlying technology stack centers on the Editorial Manager manuscript-tracking system for peer review workflow, with all content distributed via Springer Nature's SpringerLink platform to thousands of institutions worldwide.

Adis monetizes through multiple revenue streams: institutional subscriptions, article processing charges (APCs) for open access, paid VIP Service for accelerated 30-day publication, fees for digital features and enhancements, and the Reactions Weekly newsletter subscription. The primary customer segments are pharmaceutical and biotech companies (as funders and authors), academic medical researchers (as authors and readers), healthcare practitioners and decision-makers (as readers), and librarians/institutions managing journal subscriptions. Drug regulation and reimbursement professionals represent a secondary segment served by the Drug Safety and PharmacoEconomics titles. Go-to-market combines enterprise-level partnerships with pharmaceutical and biotech firms via the Springer Nature distribution network, community-led engagement through editorial boards of globally recognized experts, conference participation, and digital channels including social media, eTOC email alerts, podcasts, and conference presence. The company has no public revenue disclosure, no funding history, and operates as a non-independent division within Springer Nature.

Name

ADIS LTD

Legal name

Adis Journals

Website

https://adis.com

Company type

Private

Founded year

1970

Operating status

Operating

Short description

Adis Ltd is a medical and pharmaceutical publishing company operating a portfolio of over 30 drug-focused peer-reviewed journals, drug safety newsletters, and drug review services. Operating as a subsidiary of Springer Nature, it serves pharmaceutical companies, academic researchers, healthcare practitioners, and institutional libraries globally.

Ownership category

akta.pro rank

Product category

Medical Journal Publishing

NAICS

Periodical Publishers (51312), Newspaper, Periodical, Book, and Directory Publishers (5131)

SIC

Periodicals: Publishing Or Publishing & Printing (2721)

akta.pro primary industry

Medical Writing & Publications (Clinical/Safety/HEOR) (HLAGALAG)

akta.pro secondary industries

Academic & Scholarly Journals Publishing (Peer-Reviewed) (MPAJABAC), Medical & Clinical Reference (Physicians, Nursing, Allied Health) (EDAGAGAA)

Keywords

• Medical journal publishing
• Peer-reviewed journals
• Pharmacovigilance content
• Drug safety reporting
• Pharmaceutical publishing services

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Subscription Journal Publishing: Traditional subscription-based access to peer-reviewed medical journals across all therapeutic areas, available via Springer Nature platforms to thousands of institutions worldwide
2. Open Access Publishing (Article Processing Charges): Authors pay article processing charges to make articles freely accessible immediately upon publication. Fully open access journals and OpenChoice options available across portfolio
3. VIP Service Fees: Accelerated publication service with administrative fees for priority processing, submission to first decision in 15 days guaranteed, and publication in 30 days
4. Digital Features and Enhancements: Fees for digital features (videos, podcasts, infographics) and plain language summaries submitted after manuscript acceptance
5. Reactions Weekly Newsletter: Drug safety newsletter subscription monitoring developments across indexed journals and pharmaceutical industry sources

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Adis publishes a portfolio of more than 30 peer-reviewed medical journals focused on drugs, devices, diagnostics, and other therapeutic interventions, spanning all therapeutic areas. The company also publishes the Reactions Weekly drug safety newsletter, runs the Adis Drug Reviews program of clinically relevant drug evaluations, and offers premium author services including the VIP accelerated publication service and Digital Features enhancements, all distributed through the Springer Nature SpringerLink platform.

Product overview

Adis is a medical and pharmaceutical publishing company offering over 30 peer-reviewed journals organized into three main tiers: Premier Journals (established titles with strong metrics and traditional subscription options), Rapid+ Journals (open access with rapid publication timelines and personalized service), and Open Access Journals (fully open access titles). The portfolio includes specialized sub-brands such as Adis Drug Reviews (definitive drug evaluations, Q&As, and biosimilar briefs), the Reactions Weekly drug safety newsletter, and Digital Features & Plain Language Summaries (enhancements like videos, podcasts, infographics). All content is accessible via SpringerLink. Key services include the VIP Service (accelerated 30-day publication), Pre-Submission Enquiry Service, Article Metrics, SharedIt content sharing, and manuscript cascading options. Journals span therapeutic areas including cardiovascular, dermatology, diabetes, neurology, oncology, infectious diseases, pharmacoeconomics, and more, serving healthcare practitioners, researchers, pharmaceutical industry professionals, and decision-makers.

Differentiator

Problem solved

Functional benefit

Brands

• Reactions Weekly: A newsletter focused on drug safety that delivers concise summaries of the latest findings, regulatory updates, and safety reports from across the global pharmaceutical landscape.
• Adis Premier Journals
• Adis Rapid+ Journals
• Adis Open Access Journals
• Adis VIP Service

Quantifiable outcome

• Peer review turnaround in 2 weeks for Rapid+ Journals
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration13 records

Feature5 records

Partnerships

One partnership is on record.

• Springer NaturecoreOEM/ Whitelabel/ Licensing PartnerAdis is part of Springer Nature group, leveraging the parent company's global content platforms, distribution network, and infrastructure. Adis journals are published by Springer Nature and available through SpringerLink to thousands of institutions worldwide. The relationship provides Adis with access to Springer Nature's global content platforms, superior search engine optimization, semantic linking, and institutional distribution network.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Elsevier (RELX Group): Largest scientific, technical, and medical publisher with flagship drug/clinical titles (The Lancet, International Journal of Pharmaceutics). Directly competes with Adis for pharma authors and institutional subscription dollars.
• Springer Nature: Adis's parent company and the largest academic publisher globally. Comparable because Adis journals are hosted on SpringerLink and Springer Nature provides distribution, SEO, and institutional sales; overlapping portfolio in medical and life sciences publishing.
• Taylor & Francis (Informa): Large academic publisher with extensive pharmaceutical and clinical medicine journals. Comparable as a competing venue for drug-focused authors and as a Springer Nature competitor in the institutional 'big deal' market.
• SAGE Publications: Independent academic publisher with growing pharmaceutical and life sciences journal portfolio and open access initiatives. Comparable as a competing subscription+OA venue for medical and pharmaceutical authors.
• Wolters Kluwer Health: Medical publisher with deep pharma and clinical content (Lippincott, Ovid platform). Directly comparable in serving pharmaceutical professionals and clinicians through journals, databases, and pharmacovigilance-adjacent content.

Direct peers

• Wiley: Major publisher with strong pharmaceutical sciences portfolio (British Journal of Clinical Pharmacology, Journal of Clinical Pharmacy and Therapeutics) and open access transition strategy directly paralleling Adis's Premier/Rapid+/OA tiers.
• Karger Publishers: Independent medical and scientific publisher with strong clinical pharmacology and drug research titles. Closely comparable in niche pharmaceutical publishing with subscription+hybrid OA models.
• Mary Ann Liebert, Inc. Independent publisher focused on biotechnology, pharma, and clinical medicine journals (e.g., Genetic Engineering & Biotechnology News, Journal of Aerosol Medicine). Comparable as a niche pharma/biotech focused journal publisher competing for similar authors.
• Thieme Medical Publishers: Medical specialty publisher with pharmaceutical and clinical drug titles. Comparable in therapeutic-area journal publishing for clinicians and pharmaceutical professionals.

Emerging players

• BMJ (British Medical Journal Publishing Group): Medical publisher with growing drug evaluation and clinical pharmacology content. Comparable as a competing high-impact medical journal venue for pharmaceutical and clinical authors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AdisJournals

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ADIS LTD